Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Swine Health Market by Disease (Aujeszky's Disease (AD), Classical Swine Fever (CSF), Actinobacillus Pleuropneumonia, Mycoplasma Hyopneumoniae, Swine Enteric Coronavirus Disease, Porcine Reproductive and Respiratory Syndrome (PRRS), Salmonella) and by Route of Administration (Injectable, Oral): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03181

Pages: NA

Charts: NA

Tables: NA

Swine health is associated with the diseases caused due to pigs and the development of therapeutics to prevent the related ailments and disorders. Pig breeding can lead to many diseases such as reproductive disease and congenital malformations. Hence, governmental organizations are launching programs to protect and enhance the health of swine, which reduces the effect of swine diseases on humans.

Increase in incidences of diseases through swine drive the market. However, high cost associated with swine health especially in the developing countries impede the market growth. Moreover, key market players investing in R&D activities to develop novel therapeutics to address unmet medical needs create lucrative opportunities.

Swine health market is segmented based on diseases, route of administration, and geography. Based on diseases, the market is divided into aujeszkys disease (AD), classical swine fever (CSF), actinobacillus pleuropneumonia, mycoplasma hyopneumoniae, swine enteric coronavirus disease, porcine reproductive and respiratory syndrome (PRRS), and salmonella. Based on route of administration, the market is classified into injectable and oral. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Neogen Co, Norbrook Group, Orion Pharma, Phibro Animal Health, Vetoquinol Animal Health Pvt Ltd, Bio-Vet, Dechra Pharmaceuticals PLC, ECO Animal Health, Huvepharma SEA Private Limited, and Indian Immunologicals are provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global swine health market.
  • In-depth analysis is conducted by constructing market estimations for key market segments.
  • This study that evaluates the competitive landscape and value chain is taken into account to help understand the competitive environment globally.
  • Comprehensive analysis of factors that drive and restrict the growth of the global swine health market is provided.
  • This report provides the quantitative analysis of the current market and estimations which assists in identifying prevailing market opportunities
  • Comprehensive analysis of all regions is provided that determines prevailing opportunities in these regions.

 Key Market Segments

  • By Disease
    • Aujeszky's Disease (AD)
    • Classical Swine Fever (CSF)
    • Actinobacillus Pleuropneumonia
    • Mycoplasma Hyopneumoniae
    • Swine Enteric Coronavirus Disease
    • Porcine Reproductive and Respiratory Syndrome (PRRS)
    • Salmonella
  • By Route of Administration
    • Injectable
    • Oral
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Turkey
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bio-Vet
  • Huvepharma SEA Private Limited
  • Vetoquinol Animal Health Pvt Ltd
  • Indian Immunologicals
  • Neogen Co
  • ECO Animal Health
  • Phibro Animal Health
  • Dechra Pharmaceuticals PLC
  • Orion Pharma
  • Norbrook Group

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: SWINE HEALTH MARKET, BY DISEASE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Disease

    • 4.2. Aujeszky's Disease (AD)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Classical Swine Fever (CSF)

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Actinobacillus Pleuropneumonia

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Mycoplasma Hyopneumoniae

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Swine Enteric Coronavirus Disease

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Porcine Reproductive And Respiratory Syndrome (PRRS)

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Salmonella

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: SWINE HEALTH MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Injectable

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Oral

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: SWINE HEALTH MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Disease

      • 6.2.3. Market Size and Forecast, By Route Of Administration

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Swine Health Market

        • 6.2.5.1. Market Size and Forecast, By Disease
        • 6.2.5.2. Market Size and Forecast, By Route Of Administration

      • 6.2.6. Canada Swine Health Market

        • 6.2.6.1. Market Size and Forecast, By Disease
        • 6.2.6.2. Market Size and Forecast, By Route Of Administration

      • 6.2.7. Mexico Swine Health Market

        • 6.2.7.1. Market Size and Forecast, By Disease
        • 6.2.7.2. Market Size and Forecast, By Route Of Administration

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Disease

      • 6.3.3. Market Size and Forecast, By Route Of Administration

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Swine Health Market

        • 6.3.5.1. Market Size and Forecast, By Disease
        • 6.3.5.2. Market Size and Forecast, By Route Of Administration

      • 6.3.6. Germany Swine Health Market

        • 6.3.6.1. Market Size and Forecast, By Disease
        • 6.3.6.2. Market Size and Forecast, By Route Of Administration

      • 6.3.7. Italy Swine Health Market

        • 6.3.7.1. Market Size and Forecast, By Disease
        • 6.3.7.2. Market Size and Forecast, By Route Of Administration

      • 6.3.8. Spain Swine Health Market

        • 6.3.8.1. Market Size and Forecast, By Disease
        • 6.3.8.2. Market Size and Forecast, By Route Of Administration

      • 6.3.9. UK Swine Health Market

        • 6.3.9.1. Market Size and Forecast, By Disease
        • 6.3.9.2. Market Size and Forecast, By Route Of Administration

      • 6.3.10. Russia Swine Health Market

        • 6.3.10.1. Market Size and Forecast, By Disease
        • 6.3.10.2. Market Size and Forecast, By Route Of Administration

      • 6.3.11. Rest Of Europe Swine Health Market

        • 6.3.11.1. Market Size and Forecast, By Disease
        • 6.3.11.2. Market Size and Forecast, By Route Of Administration

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Disease

      • 6.4.3. Market Size and Forecast, By Route Of Administration

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Swine Health Market

        • 6.4.5.1. Market Size and Forecast, By Disease
        • 6.4.5.2. Market Size and Forecast, By Route Of Administration

      • 6.4.6. Japan Swine Health Market

        • 6.4.6.1. Market Size and Forecast, By Disease
        • 6.4.6.2. Market Size and Forecast, By Route Of Administration

      • 6.4.7. India Swine Health Market

        • 6.4.7.1. Market Size and Forecast, By Disease
        • 6.4.7.2. Market Size and Forecast, By Route Of Administration

      • 6.4.8. South Korea Swine Health Market

        • 6.4.8.1. Market Size and Forecast, By Disease
        • 6.4.8.2. Market Size and Forecast, By Route Of Administration

      • 6.4.9. Australia Swine Health Market

        • 6.4.9.1. Market Size and Forecast, By Disease
        • 6.4.9.2. Market Size and Forecast, By Route Of Administration

      • 6.4.10. Thailand Swine Health Market

        • 6.4.10.1. Market Size and Forecast, By Disease
        • 6.4.10.2. Market Size and Forecast, By Route Of Administration

      • 6.4.11. Malaysia Swine Health Market

        • 6.4.11.1. Market Size and Forecast, By Disease
        • 6.4.11.2. Market Size and Forecast, By Route Of Administration

      • 6.4.12. Indonesia Swine Health Market

        • 6.4.12.1. Market Size and Forecast, By Disease
        • 6.4.12.2. Market Size and Forecast, By Route Of Administration

      • 6.4.13. Rest of Asia Pacific Swine Health Market

        • 6.4.13.1. Market Size and Forecast, By Disease
        • 6.4.13.2. Market Size and Forecast, By Route Of Administration

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Disease

      • 6.5.3. Market Size and Forecast, By Route Of Administration

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Swine Health Market

        • 6.5.5.1. Market Size and Forecast, By Disease
        • 6.5.5.2. Market Size and Forecast, By Route Of Administration

      • 6.5.6. South Africa Swine Health Market

        • 6.5.6.1. Market Size and Forecast, By Disease
        • 6.5.6.2. Market Size and Forecast, By Route Of Administration

      • 6.5.7. Saudi Arabia Swine Health Market

        • 6.5.7.1. Market Size and Forecast, By Disease
        • 6.5.7.2. Market Size and Forecast, By Route Of Administration

      • 6.5.8. UAE Swine Health Market

        • 6.5.8.1. Market Size and Forecast, By Disease
        • 6.5.8.2. Market Size and Forecast, By Route Of Administration

      • 6.5.9. Argentina Swine Health Market

        • 6.5.9.1. Market Size and Forecast, By Disease
        • 6.5.9.2. Market Size and Forecast, By Route Of Administration

      • 6.5.10. Rest of LAMEA Swine Health Market

        • 6.5.10.1. Market Size and Forecast, By Disease
        • 6.5.10.2. Market Size and Forecast, By Route Of Administration

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Neogen Co

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Norbrook Group

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Orion Pharma

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Phibro Animal Health

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Vetoquinol Animal Health Pvt Ltd

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Bio-Vet

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Dechra Pharmaceuticals PLC

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. ECO Animal Health

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Huvepharma SEA Private Limited

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Indian Immunologicals

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL SWINE HEALTH MARKET, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL SWINE HEALTH MARKET FOR AUJESZKY'S DISEASE (AD), BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL SWINE HEALTH MARKET FOR CLASSICAL SWINE FEVER (CSF), BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL SWINE HEALTH MARKET FOR ACTINOBACILLUS PLEUROPNEUMONIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL SWINE HEALTH MARKET FOR MYCOPLASMA HYOPNEUMONIAE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL SWINE HEALTH MARKET FOR SWINE ENTERIC CORONAVIRUS DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL SWINE HEALTH MARKET FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL SWINE HEALTH MARKET FOR SALMONELLA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL SWINE HEALTH MARKET, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL SWINE HEALTH MARKET FOR INJECTABLE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL SWINE HEALTH MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL SWINE HEALTH MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA SWINE HEALTH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 16. U.S. SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 18. CANADA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 19. CANADA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE SWINE HEALTH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 26. FRANCE SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 28. GERMANY SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 29. ITALY SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 30. ITALY SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 32. SPAIN SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 33. UK SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 34. UK SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 36. RUSSIA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 38. REST OF EUROPE SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC SWINE HEALTH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 42. CHINA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 43. CHINA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 45. JAPAN SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 46. INDIA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 47. INDIA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 49. SOUTH KOREA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 51. AUSTRALIA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 53. THAILAND SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 55. MALAYSIA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 57. INDONESIA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA SWINE HEALTH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 64. BRAZIL SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH AFRICA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 68. SAUDI ARABIA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 69. UAE SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 70. UAE SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 72. ARGENTINA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA SWINE HEALTH, BY DISEASE, 2025-2033 ($MILLION)
  • TABLE 74. REST OF LAMEA SWINE HEALTH, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 75. NEOGEN CO: KEY EXECUTIVES
  • TABLE 76. NEOGEN CO: COMPANY SNAPSHOT
  • TABLE 77. NEOGEN CO: OPERATING SEGMENTS
  • TABLE 78. NEOGEN CO: PRODUCT PORTFOLIO
  • TABLE 79. NEOGEN CO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. NORBROOK GROUP: KEY EXECUTIVES
  • TABLE 81. NORBROOK GROUP: COMPANY SNAPSHOT
  • TABLE 82. NORBROOK GROUP: OPERATING SEGMENTS
  • TABLE 83. NORBROOK GROUP: PRODUCT PORTFOLIO
  • TABLE 84. NORBROOK GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. ORION PHARMA: KEY EXECUTIVES
  • TABLE 86. ORION PHARMA: COMPANY SNAPSHOT
  • TABLE 87. ORION PHARMA: OPERATING SEGMENTS
  • TABLE 88. ORION PHARMA: PRODUCT PORTFOLIO
  • TABLE 89. ORION PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. PHIBRO ANIMAL HEALTH: KEY EXECUTIVES
  • TABLE 91. PHIBRO ANIMAL HEALTH: COMPANY SNAPSHOT
  • TABLE 92. PHIBRO ANIMAL HEALTH: OPERATING SEGMENTS
  • TABLE 93. PHIBRO ANIMAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 94. PHIBRO ANIMAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. VETOQUINOL ANIMAL HEALTH PVT LTD: KEY EXECUTIVES
  • TABLE 96. VETOQUINOL ANIMAL HEALTH PVT LTD: COMPANY SNAPSHOT
  • TABLE 97. VETOQUINOL ANIMAL HEALTH PVT LTD: OPERATING SEGMENTS
  • TABLE 98. VETOQUINOL ANIMAL HEALTH PVT LTD: PRODUCT PORTFOLIO
  • TABLE 99. VETOQUINOL ANIMAL HEALTH PVT LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. BIO-VET: KEY EXECUTIVES
  • TABLE 101. BIO-VET: COMPANY SNAPSHOT
  • TABLE 102. BIO-VET: OPERATING SEGMENTS
  • TABLE 103. BIO-VET: PRODUCT PORTFOLIO
  • TABLE 104. BIO-VET: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. DECHRA PHARMACEUTICALS PLC: KEY EXECUTIVES
  • TABLE 106. DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • TABLE 107. DECHRA PHARMACEUTICALS PLC: OPERATING SEGMENTS
  • TABLE 108. DECHRA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
  • TABLE 109. DECHRA PHARMACEUTICALS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. ECO ANIMAL HEALTH: KEY EXECUTIVES
  • TABLE 111. ECO ANIMAL HEALTH: COMPANY SNAPSHOT
  • TABLE 112. ECO ANIMAL HEALTH: OPERATING SEGMENTS
  • TABLE 113. ECO ANIMAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 114. ECO ANIMAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. HUVEPHARMA SEA PRIVATE LIMITED: KEY EXECUTIVES
  • TABLE 116. HUVEPHARMA SEA PRIVATE LIMITED: COMPANY SNAPSHOT
  • TABLE 117. HUVEPHARMA SEA PRIVATE LIMITED: OPERATING SEGMENTS
  • TABLE 118. HUVEPHARMA SEA PRIVATE LIMITED: PRODUCT PORTFOLIO
  • TABLE 119. HUVEPHARMA SEA PRIVATE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. INDIAN IMMUNOLOGICALS: KEY EXECUTIVES
  • TABLE 121. INDIAN IMMUNOLOGICALS: COMPANY SNAPSHOT
  • TABLE 122. INDIAN IMMUNOLOGICALS: OPERATING SEGMENTS
  • TABLE 123. INDIAN IMMUNOLOGICALS: PRODUCT PORTFOLIO
  • TABLE 124. INDIAN IMMUNOLOGICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL SWINE HEALTH MARKET SEGMENTATION
  • FIGURE 2. GLOBAL SWINE HEALTH MARKET
  • FIGURE 3. SEGMENTATION SWINE HEALTH MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN SWINE HEALTH MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSWINE HEALTH MARKET
  • FIGURE 11. SWINE HEALTH MARKET SEGMENTATION, BY BY DISEASE
  • FIGURE 12. SWINE HEALTH MARKET FOR AUJESZKY'S DISEASE (AD), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. SWINE HEALTH MARKET FOR CLASSICAL SWINE FEVER (CSF), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. SWINE HEALTH MARKET FOR ACTINOBACILLUS PLEUROPNEUMONIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. SWINE HEALTH MARKET FOR MYCOPLASMA HYOPNEUMONIAE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. SWINE HEALTH MARKET FOR SWINE ENTERIC CORONAVIRUS DISEASE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. SWINE HEALTH MARKET FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. SWINE HEALTH MARKET FOR SALMONELLA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. SWINE HEALTH MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 20. SWINE HEALTH MARKET FOR INJECTABLE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. SWINE HEALTH MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: SWINE HEALTH MARKET
  • FIGURE 28. TOP PLAYER POSITIONING, 2024
  • FIGURE 29. NEOGEN CO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. NEOGEN CO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. NEOGEN CO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. NORBROOK GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. NORBROOK GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. NORBROOK GROUP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. ORION PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. ORION PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. ORION PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. PHIBRO ANIMAL HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. PHIBRO ANIMAL HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. PHIBRO ANIMAL HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. VETOQUINOL ANIMAL HEALTH PVT LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. VETOQUINOL ANIMAL HEALTH PVT LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. VETOQUINOL ANIMAL HEALTH PVT LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. BIO-VET: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. BIO-VET: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. BIO-VET: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. DECHRA PHARMACEUTICALS PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. DECHRA PHARMACEUTICALS PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. DECHRA PHARMACEUTICALS PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. ECO ANIMAL HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. ECO ANIMAL HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. ECO ANIMAL HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. HUVEPHARMA SEA PRIVATE LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. HUVEPHARMA SEA PRIVATE LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. HUVEPHARMA SEA PRIVATE LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. INDIAN IMMUNOLOGICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. INDIAN IMMUNOLOGICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. INDIAN IMMUNOLOGICALS: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Swine Health Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved